Two Agents Offer Similar pCR Rates in ETNA Breast Cancer Trial (CME/CE)

(MedPage Today) -- Tumor subtype most significant factor for response among ERBB/HER2-negative patients
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news